香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）會（「董事會」）董事長已向董事會提議採納一項計劃（「建議H 股回購計劃」），據此，本公司可視乎市況，並不時根據本公司股東（「股東」）於股 東大會上批准的回購H股的一般性授權（「建議回購授權」），於公開市場回購本公 司H股（「H股」）。 目前預計根據建議H股回購計劃，本公司將動用不超過人民幣100百萬元，於公開 市場回購最多550萬股H股。 為免生疑問，建議H股回購計劃的實施須待(i)董事會批准；及(ii)股東於本公司即 將於2026年5月22日舉行的股東週年大會上批准建議回購授權後，方可作實。回 購H股的時間、價格及金額將根據市況及其他因素釐定。根據聯交所證券上市規 則（「上市規則」），每次回購H股的實際購買價格不得高於緊接該次回購前五個交 易日H股平均收市價的5%或以上。本公司將以其現有可用現金為建議H股回購計 劃提供資金。 LEPU SCIENTECH MEDICAL TECHN ...

第 1 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 樂普心泰醫療科技(上海)股份有限公司 | | | 股份代號 | 02291 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年十二月三十一日止年度末期股息 | | 公告日期 | 2026年3月30日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.5 RMB | | 股東批准日期 | 2026年5月22日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | HKD， 金 ...

Financial Performance - Revenue increased by 11.9% from RMB 471.6 million for the year ending December 31, 2024, to RMB 527.9 million for the year ending December 31, 2025[5]. - Gross profit rose by 5.4% from RMB 424.0 million for the year ending December 31, 2024, to RMB 447.0 million for the year ending December 31, 2025[5]. - Net profit attributable to shareholders decreased by 2.4% from RMB 245.6 million for the year ending December 31, 2024, to RMB 239.7 million for the year ending December 31, 2025[5]. - The company proposed a final dividend of RMB 0.5 per share (tax included) for the year ending December 31, 2025, down from RMB 0.62 per share (tax included) for the year ending December 31, 2024[5]. - The company's operating revenue is projected to increase from RMB 471.6 million for the year ending December 31, 2024, to RMB 527.9 million for the year ending December 31, 2025, representing an 11.94% growth[24]. - Net profit for 2025 was ¥239,727,919.85, a decrease of 2.9% from ¥245,559,893.33 in 2024[71]. - The total comprehensive income attributable to the parent company for the period was RMB 239,727,919.85, compared to RMB 245,559,893.33 in the previous period, reflecting a decrease of approximately 2.3%[73]. - Basic and diluted earnings per share for the period were both RMB 0.69, down from RMB 0.71 in the previous period, indicating a decline of about 2.8%[73]. Research and Development - R&D expenses grew by 0.3% from RMB 58.0 million for the year ending December 31, 2024, to RMB 58.1 million for the year ending December 31, 2025[5]. - The company is focusing on biodegradable medical devices and exploring advanced fields such as heart valves and mechanical circulatory support[6]. - The company is in the clinical preparation phase for several new products, including the biodegradable left atrial appendage delivery system[8]. - The company is committed to exploring new technologies and innovations in structural heart disease, including biodegradable technology applications[17]. - Research and development expenses totaled RMB 58,147,363.10 for the year ended December 31, 2025, compared to RMB 46,000,000.00 in 2024, an increase of approximately 26.25%[100]. Product Development and Commercialization - The company has a total of 32 commercialized products, with 3 products under registration review and 27 products in various stages of development[6]. - The company has successfully commercialized several products, including the MemoSorb® biodegradable occluder system and various heart occluders[7]. - The company has commercialized 11 congenital heart disease occluder products, with the third-generation MemoCarna® occluder series becoming a key product since its approval in 2020[9]. - The fourth-generation MemoSorb® biodegradable occluder system received regulatory approval in 2022 and is expected to achieve commercialization by August 2024[9]. - The third-generation MemoSorb® biodegradable foramen ovale occluder was approved for market launch in September 2023, gaining significant market attention and sales performance[11]. - The company is developing a transcatheter aortic valve system for aortic regurgitation patients, currently in the clinical initiation phase[13]. - The company plans to continue expanding its product offerings in the structural heart disease market, leveraging existing technological and market resources[14]. - The company has entered the Mechanical Circulatory Support (MCS) device sector, with plans to start clinical trials for its short-term support system in the second half of 2026[15]. Sales and Market Strategy - The company plans to enhance its marketing team and expand its sales network in China, aiming to improve brand recognition and market penetration[23]. - The company aims to optimize its sales strategies for the oval foramen closure market, targeting a 30% increase in sales volume compared to the previous year[28]. - The company will actively explore overseas sales channels and enhance the international market presence of its products, focusing on biodegradable occluders and valves[23]. - Sales revenue from congenital heart disease occluder products is expected to rise from RMB 245.9 million (52.2% of total revenue) in 2024 to RMB 253.3 million (48.0% of total revenue) in 2025, marking a 3.0% increase[26]. - Sales revenue from cardiogenic stroke prevention products is anticipated to decrease from RMB 143.9 million (30.5% of total revenue) in 2024 to RMB 137.0 million (26.0% of total revenue) in 2025, reflecting a 4.8% decline[27]. - Sales revenue from access products is projected to grow from RMB 81.3 million (17.2% of total revenue) in 2024 to RMB 83.0 million (15.6% of total revenue) in 2025, indicating a 2.1% increase[29]. Financial Position and Liquidity - As of December 31, 2025, the total cash and cash equivalents increased by 2.7% to RMB 1,151.3 million from RMB 1,121.3 million as of December 31, 2024, primarily due to net cash generated from operating activities of RMB 221.1 million[47]. - Current assets increased by 2.6% to RMB 1,367.6 million as of December 31, 2025, compared to RMB 1,333.0 million as of December 31, 2024, driven by increases in cash, accounts receivable, and inventory[49]. - The current ratio improved to 23.5 times as of December 31, 2025, compared to 16.8 times as of December 31, 2024[60]. - The debt-to-asset ratio decreased to 3.0% as of December 31, 2025, from 4.1% as of December 31, 2024[60]. - The company had no outstanding borrowings or unused bank financing as of December 31, 2024, and December 31, 2025[48]. - The company has no significant concerns regarding its ability to continue as a going concern for the next 12 months[81]. Cost Management - The company's operating costs are expected to rise significantly from RMB 47.6 million in 2024 to RMB 81.0 million in 2025, representing a 70.1% increase[32]. - Raw materials and consumables cost increased by 175.9% from RMB 14.5 million in 2024 to RMB 40.1 million in 2025, primarily due to the commercialization of heart valve products and increased production volume of other products[34]. - Labor costs rose by 6.0% from RMB 15.2 million in 2024 to RMB 16.1 million in 2025, attributed to increased production volume and workforce[35]. - Amortization of intangible assets increased by 52.3% from RMB 12.6 million in 2024 to RMB 19.2 million in 2025, due to the amortization of patents and medical device registrations[35]. - Sales expenses surged by 50.2% from RMB 71.1 million in 2024 to RMB 106.8 million in 2025, driven by the expansion of the marketing team and increased promotional activities for new products[39]. Corporate Governance and Compliance - The financial statements were approved by the board of directors on March 30, 2026[79]. - The company adheres to the accounting standards set forth by the Ministry of Finance, ensuring that the financial statements accurately reflect its financial position and results of operations[82]. - The audit committee reviewed the consolidated financial statements for the year ending December 31, 2025, ensuring compliance with accounting principles[113]. - The annual general meeting is scheduled for May 22, 2026[115].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.* 樂普心泰醫療科技（上海）股份有限公司 董事會會議通告 樂普心泰醫療科技（上海）股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，本公司將於2026年3月30日（星期一）舉行董事會會議，藉以（其中包括）考慮 及批准本公司及其附屬公司截至2025年12月31日止年度的全年業績及其發佈，並 考慮建議派發末期股息（如有）。 承董事會命 樂普心泰醫療科技（上海）股份有限公司 陳娟女士 董事長兼執行董事 中華人民共和國，上海 2026年3月18日 （於中華人民共和國註冊成立的股份有限公司） 於本公告日期，董事會包括執行董事陳娟女士；非執行董事張昱昕女士、付山先 生及朱觀富先生；以及獨立非執行董事陳嘉麗女士、鄭玉峰先生及鄭軍偉先生。 * 本公司註冊為香港法例第622章《公司條例》所定義的非香港公司，以 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 樂普心泰醫療科技（上海）股份有限公司 (「本公司」) 備註： 因本公司是於中華人民共和國註冊成立，「法定股本」之概念不適用於本公司。於I節中所示的資料是指本公司的「註冊股本」。 第 1 頁 共 10 頁 v 1.2.0 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | RMB ...

Group 1 - The core viewpoint is that Xintai Medical (02291) has shown a fluctuating upward trend in its stock price over the past week, with a cumulative increase of 5.43% and a volatility of 8.68% [1] - Technical indicators suggest an improvement in short-term momentum, although the stock price remains below key moving averages, indicating an overall consolidation phase [1] Group 2 - Institutions maintain a positive outlook on Xintai Medical, with the latest coverage indicating that all institutions have given "Buy" or "Add" ratings, suggesting a potential upside of approximately 29.4% compared to the current stock price [2] - The consensus optimistic sentiment is primarily based on the company's fundamentals and industry position, but attention should be paid to the overall volatility risk in the Hong Kong medical sector [2]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 樂普心泰醫療科技（上海）股份有限公司 (「本公司」) 呈交日期: 2026年2月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | 本月底法定/註冊股本總額： RM ...

截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 樂普心泰醫療科技（上海）股份有限公司 (「本公司」) FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 | RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 | RMB | | 346,749,997 ...

Group 1 - The company, Heartway Medical (02291), announced that Mr. Li Jianwei has resigned from several positions effective December 30, 2025 [1] - Mr. Li's positions include: (i) Co-Company Secretary; (ii) Agent for receiving legal documents and notices in Hong Kong as per the Hong Kong Stock Exchange Listing Rules; and (iii) Authorized representative under the Companies Ordinance and Listing Rules [1] - Following Mr. Li's resignation, Ms. Yang Lishan has been appointed to the aforementioned positions effective December 30, 2025 [1]

Group 1 - The company Xintai Medical (02291) announced the resignation of Mr. Li Jianwei from multiple positions effective December 30, 2025 [1] - Mr. Li's positions include Co-Company Secretary, legal process document receiving agent, and authorized representative under relevant Hong Kong regulations [1] - Following Mr. Li's resignation, Ms. Yang Lishan has been appointed to the aforementioned positions, also effective December 30, 2025 [1]